S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
The single greatest medical breakthrough of all time? (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Open vs. Anonymous Employee Feedback — Which is Better?
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
The single greatest medical breakthrough of all time? (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Open vs. Anonymous Employee Feedback — Which is Better?
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
The single greatest medical breakthrough of all time? (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Open vs. Anonymous Employee Feedback — Which is Better?
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
The single greatest medical breakthrough of all time? (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Open vs. Anonymous Employee Feedback — Which is Better?
NASDAQ:ATRA

Atara Biotherapeutics (ATRA) Price Target & Analyst Ratings

$1.77
-0.15 (-7.81%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$1.75
▼
$1.93
50-Day Range
$1.77
▼
$3.04
52-Week Range
$1.75
▼
$9.34
Volume
1.88 million shs
Average Volume
1.30 million shs
Market Capitalization
$173.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.86
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Atara Biotherapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$19.25
987.57% Upside
High Prediction$50.00
Average Prediction$19.25
Low Prediction$3.00
TypeCurrent
5/29/22 to 5/29/23		1 Month Ago
4/29/22 to 4/29/23		3 Months Ago
2/28/22 to 2/28/23		1 Year Ago
5/29/21 to 5/29/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$19.25$19.25$19.25$28.29
Predicted Upside987.57% Upside237.13% Upside237.13% Upside182.01% Upside
Get Atara Biotherapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.


ATRA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATRA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Atara Biotherapeutics Stock vs. The Competition

TypeAtara BiotherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.14
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside987.57% Upside490.06% Upside31.06% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/9/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$25.00+396.03%
2/9/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$29.00 ➝ $27.00+435.71%
2/7/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$31.00+474.07%
8/9/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetSell$4.00 ➝ $3.00-32.13%
7/20/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeNeutral ➝ Sell$8.00 ➝ $3.00-17.58%
7/13/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$67.00 ➝ $50.00+1,172.26%
7/13/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$16.00 ➝ $5.00-42.26%
7/13/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Neutral$10.00+15.47%
(Data available from 5/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ATRA Price Target - Frequently Asked Questions

What is Atara Biotherapeutics's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Atara Biotherapeutics stock is Hold based on the current 2 sell ratings, 2 hold ratings and 3 buy ratings for ATRA. The average twelve-month price prediction for Atara Biotherapeutics is $19.25 with a high price target of $50.00 and a low price target of $3.00. Learn more on ATRA's analyst rating history.

Do Wall Street analysts like Atara Biotherapeutics more than its competitors?

Analysts like Atara Biotherapeutics less than other Medical companies. The consensus rating for Atara Biotherapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how ATRA compares to other companies.

Does Atara Biotherapeutics's stock price have much upside?

According to analysts, Atara Biotherapeutics's stock has a predicted upside of 237.13% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ATRA) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -